This classification has established IDH-wildtype GBM and IDH-mutant GBM; IDH-wildtype GBM has a worse prognosis, with a survival rate around 10 to 15 months, it often has mutations in the TERT promoter (76%), and sometimes harbours alterations in TP53 (27%) and PTEN (24%). The gene discussed is TP53; the disease is glioblastoma.